Please check your internet connection and try again.
# Hyaluronic acid
## Overview
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan found in various connective tissues, synovial fluid, and ocular tissues. It acts as a lubricant and shock absorber. As a pharmaceutical agent, it is available in various formulations for different routes of administration.
## Primary Indications
* **Intra-articular injection:** Osteoarthritis of the knee.
* **Ophthalmic solution:** Ocular surface disease (e.g., dry eye), intraocular lens insertion during cataract surgery.
* **Topical:** Wound healing, osteoarthritis (oral or topical formulations exist but have less robust evidence).
## Adult Dosing
* **Osteoarthritis of the knee (intra-articular):**
* **Common formulations:** Typically 20 mg/2 mL (10 mg/mL) or 60 mg/6 mL (10 mg/mL) injected intra-articularly once a week for 3-5 weeks. Some preparations allow a single 60 mg injection.
* **Maximum:** Treatment courses may be repeated every 6 months.
* **Ophthalmic (dry eye):**
* **Common formulations:** 0.1% to 0.2% solutions.
* **Dosing:** 1-2 drops instilled into the affected eye(s) as needed, up to 4-6 times daily. Some higher concentrations may be used less frequently.
* **Intraocular surgery (viscosurgical device):**
* **Dosing:** Administered intraocularly by a surgeon during procedures like cataract surgery to maintain space and protect tissues. Specific volume and concentration depend on the surgical technique and product.
## Pediatric Dosing
* **Intra-articular:** Limited data; generally not recommended or used off-label in pediatric populations for osteoarthritis.
* **Ophthalmic:** Used in pediatric patients for dry eye, similar to adults (e.g., 0.1% to 0.2% solution, 1-2 drops as needed). Safety and efficacy in children under a certain age may not be established by all manufacturers.
## Dose Adjustments
No specific dose adjustments are typically required for hepatic or renal impairment, as HA has minimal systemic absorption.
## Contraindications
* Known hypersensitivity to hyaluronic acid or any component of the formulation.
* Active infection in or around the joint to be injected (for intra-articular preparations).
* Skin infection over the injection site (for intra-articular preparations).
## Adverse Effects
* **Intra-articular:** Localized pain, swelling, stiffness, warmth, redness, itching, or transient effusion at the injection site. Rare: allergic reactions, joint infection.
* **Ophthalmic:** Blurred vision (transient), eye irritation, stinging, redness.
* **Systemic:** Very rare.
## Key Drug Interactions
* **Intra-articular:** Concurrent use of other intra-articular injections (e.g., corticosteroids) may increase the risk of local adverse effects or joint infection, although specific interactions are not well-defined. Consult product labeling for concurrent use guidance.
* **Ophthalmic:** Generally minimal systemic interactions. May affect the retention time of other topical ophthalmic medications.
## Monitoring
* **Intra-articular:** Monitor for signs and symptoms of joint infection (e.g., increased pain, swelling, fever) after injection.
* **Ophthalmic:** Assess for symptom relief of dry eye.
## Clinical Pearls
* Hyaluronic acid formulations vary significantly by manufacturer and indication. Always confirm the specific product and its intended use.
* For intra-articular injections, ensure aseptic technique. Inform patients to avoid strenuous activity or prolonged weight-bearing for 24-48 hours post-injection.
* Ophthalmic HA products are often preservative-free, especially those in single-use vials or multi-dose bottles designed to minimize contamination.
* The efficacy of oral or topical HA for osteoarthritis is less established compared to intra-articular injections.
***
*Disclaimer: This information is intended for clinical use and does not substitute for professional medical judgment. Always consult the most current prescribing information and relevant literature for specific patient management.*
